Neuriond enables the industrial biosynthesis of a novel compound for Treatment-resistant depression. The annual cost of depression in the EU and the US is estimated to be USD $350b including direct treatment costs. The treatment resistant depression market was valued at USD $860m in 2015 and is expected to reach USD $1,130m by 2024. There are approximately 300m patients worldwide (including 100m suffering with treatment-resistant depression) increasing 18% from 2005 to 2015. Current synthesis is costly due to number of steps and chemical reagents with commercial prices of USD $7,000-10,000 per gram (GMP).